预防特发性胃十二指肠溃疡复发性出血:双盲随机试验
这项双盲随机试验纳入228例幽门螺杆菌阴性特发性消化性溃疡出血史患者,溃疡愈合后按1:1随机接受兰索拉唑30 mg或法莫替丁40 mg每日口服共24个月;24个月内复发性上消化道出血累积发生率兰索拉唑组为0.88%,法莫替丁组为2.63%,两组相当,但不能排除小的疗效差异。
要点
- 幽门螺杆菌阴性特发性溃疡出血史患者,兰索拉唑与法莫替丁24个月复发性出血率相当。
- 兰索拉唑组24个月累积复发率0.88%,法莫替丁组2.63%(p=0.313)。
- 粗HR 0.33(95%CI 0.03-3.16,p=0.336),不能排除小的疗效差异。
核心结论
- 这项2年双盲随机试验显示,幽门螺杆菌阴性特发性溃疡出血史患者中,兰索拉唑与法莫替丁使用者的复发性出血率相当,但不能排除小的疗效差异。
研究设计与样本
- 独立于产业的雙盲随机试验,2010年至2018年纳入228例有特发性出血性溃疡史的患者,每组114例。
- 溃疡愈合后按1:1随机分配接受口服兰索拉唑30 mg或法莫替丁40 mg每日一次,共24个月。
- 主要终点为24个月内复发性上消化道出血,按意向治疗人群由独立裁定委员会判定。
主要发现
- 复发性上消化道出血:兰索拉唑组1例(十二指肠溃疡),法莫替丁组3例(2例胃溃疡和1例十二指肠溃疡)。
- 24个月复发性上消化道出血累积发生率:兰索拉唑组0.88%(95%CI 0.08%至4.37%),法莫替丁组2.63%(95%CI 0.71%至6.91%),p=0.313。
- 粗HR 0.33(95%CI 0.03至3.16),p=0.336。
- 再出血患者均未使用阿司匹林、非甾体抗炎药或其他抗血栓药物。
关键数值与推荐
- 主要终点24个月复发性上消化道出血累积发生率:兰索拉唑组0.88%(95%CI 0.08%至4.37%)vs 法莫替丁组2.63%(95%CI 0.71%至6.91%),p=0.313。
- 粗HR 0.33(95%CI 0.03至3.16),p=0.336。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出不能排除兰索拉唑与法莫替丁之间小的疗效差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with a history of Helicobacter pylori-negative idiopathic bleeding ulcers have a considerable risk of recurrent ulcer complications. We hypothesised that a proton pump inhibitor (lansoprazole) is superior to a histamine 2 receptor antagonist (famotidine) for the prevention of recurrent ulcer bleeding in such patients. DESIGN: In this industry-independent, double-blind, randomised trial, we recruited patients with a history of idiopathic bleeding ulcers. After ulcer healing, we randomly assigned (1:1) patients to receive oral lansoprazole 30 mg or famotidine 40 mg daily for 24 months. The primary endpoint was recurrent upper GI bleeding within 24 months, analysed in the intention-to-treat population as determined by an independent adjudication committee. RESULTS: Between 2010 and 2018, we enrolled 228 patients (114 patients in each study group). Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer). The cumulative incidence of recurrent upper GI bleeding in 24 months was 0.88% (95% CI 0.08% to 4.37%) in the lansoprazole arm and 2.63% (95% CI 0.71% to 6.91%) in the famotidine arm (p=0.313; crude HR 0.33, 95% CI 0.03 to 3.16, p=0.336). None of the patients who rebled used aspirin, non-steroidal anti-inflammatory drugs or other antithrombotic drugs. CONCLUSION: This 2-year, double-blind randomised trial showed that among patients with a history of H. pylori-negative idiopathic ulcer bleeding, recurrent bleeding rates were comparable between users of lansoprazole and famotidine, although a small difference in efficacy cannot be excluded. TRIAL REGISTRATION NUMBER: NCT01180179; Results.
引用
- Wong GLH, Lau LHS, Ching JYL, et al. Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. Gut. 2019. PMID: 31229990. doi:10.1136/gutjnl-2019-318715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。